静脉用地尔硫与单硝酸异山梨醇治疗不稳定型心绞痛的疗效评价

The Clinical Efficacy of Intravenous Diltazem Versus Isosorbide 5-mono-nitrate For Unstable Angina Pectoris

目的 :观察静脉用合贝爽 (地尔硫 )治疗不稳定型心绞痛的临床疗效和安全性。方法 :随机选择同期收治的 5 0例不稳定型心绞痛患者 ,分为地尔硫 组 19例和硝酸酯治疗组 31例。地尔硫 组 :以合贝爽注射剂 10mg溶于 4 0ml生理盐水中 ,10分钟内静脉注射 ,继以 4 0mg合贝爽注射剂加入 5 %葡萄糖注射液 2 5 0ml中以 10mg/h速度静滴 ,维持 2天。硝酸酯组 :以 (4 0～ 6 0 )mg鲁南欣康注射液加入 5 %葡萄糖注射液 2 5 0ml中以 (7～ 10 )mg/h的速度静滴 ,持续 2天。结果 :在症状和心电图改善方面 ,地尔硫 组疗效均显著优于硝酸酯组 (P <0 .0 5 )。结论 :地尔硫 治疗不稳定型心绞痛的临床疗效显著优于单硝酸异山梨醇 ,且安全可靠。

Objective: To observe the clinical efficacy and safety of intravenous diltazem in patients with unstable angina pectoris (UAP). Methods: The 50 UAP patients were randomly divided into two groups. The Herbesser group (19 cases) was administered Herbesser 10mg intravenously within 10 minutes firstly, and then they received continuous intravenous infusion of Herbesser (10mg/h) for two days. The Nitrate group (31 cases) received continuous intravenous infusion of isosorbide 5-mononitrate [(40～60)mg,(7～10)mg/h] for two days. Result: The clinical efficacy of the symptoms and ECG improvement in the diltazem group was significantly better than the in Nitrate group (P<0.05). Conclusion: The clinical efficacy of diltazem in treatment of UAP was significantly better than isosorbide 5-mononitrate, and it was safety.